Targeted therapies
Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma
kakameo
Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015). Article PubMed Google ...
